

Resource Summary Report

Generated by [SPARC SAWG](#) on Sep 15, 2026

NanoStringNorm

RRID:SCR_003382

Type: Tool

Proper Citation

NanoStringNorm (RRID:SCR_003382)

Resource Information

URL: <http://cran.r-project.org/web/packages/NanoStringNorm/>

Proper Citation: NanoStringNorm (RRID:SCR_003382)

Description: Software package for normalizing, diagnostics and visualization of NanoString nCounter data. Key features include an extensible environment for method comparison and new algorithm development, integrated gene and sample diagnostics, and facilitated downstream statistical analysis.

Abbreviations: NanoStringNorm

Synonyms: NanoStringNorm: Normalize NanoString miRNA and mRNA data

Resource Type: data processing software, software application, software resource

Defining Citation: [PMID:22513995](#)

Keywords: normalization, nanostring ncounter, mirna, mrna, r, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: NanoStringNorm

Resource ID: SCR_003382

Alternate IDs: OMICS_02308, biotools:nanostringnorm

Alternate URLs:

<https://www.rdocumentation.org/packages/NanoStringNorm/versions/1.2.1.1/topics/NanoStringNorm>

Record Creation Time: 20220129T080218+0000

Record Last Update: 20260912T200054+0000

Ratings and Alerts

No rating or validation information has been found for NanoStringNorm.

No alerts have been found for NanoStringNorm.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 137 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Ghiringhelli F, et al. (2026) Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. *Journal for immunotherapy of cancer*, 14(3).

Lautert-Dutra W, et al. (2026) Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer. *The Prostate*, 86(10), 1103.

Anderson EC, et al. (2025) Blood Pressure and Late Pregnancy Circulating miRNAs in the MADRES Study. *Journal of the American Heart Association*, 14(12), e040416.

Megid RA, et al. (2025) Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling. *Frontiers in molecular biosciences*, 12, 1537523.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. *iScience*, 28(5), 112333.

Trakarnsanga K, et al. (2025) MicroRNA profiles of four induced pluripotent stem cell lines derived from distinct tissues. *BMC research notes*, 18(1), 356.

Melero I, et al. (2025) Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. *Nature*, 637(8048), 1218.

Zhang Y, et al. (2025) Gamma Knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis. *eLife*, 14.

Calfa S, et al. (2025) Exploring shared microRNA profiles in liquid-based cytology and plasma as biomarkers of high-grade intraepithelial lesions. *Scientific reports*, 16(1), 828.

Bauer M, et al. (2025) HIV status alters immune cell infiltration and activation profile in women with breast cancer. *Nature communications*, 16(1), 4699.

Roesel R, et al. (2025) Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally

advanced rectal cancer. *Oncoimmunology*, 14(1), 2465015.

Raquel-Cunha A, et al. (2025) RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. *Molecular oncology*.

Santarosa Vieira AG, et al. (2024) Comprehensive microRNA expression analysis of pediatric gonadal germ cell tumors: unveiling novel biomarkers and signatures. *Molecular oncology*, 18(6), 1593.

Xu C, et al. (2024) Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer. *Cell reports. Medicine*, 5(8), 101661.

Safi R, et al. (2024) Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. *Nature communications*, 15(1), 7675.

Causin RL, et al. (2024) EV-miRNAs from breast cancer patients of plasma as potential prognostic biomarkers of disease recurrence. *Heliyon*, 10(14), e33933.

Richman J, et al. (2024) Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients. *Breast cancer research and treatment*, 206(1), 195.

Tarhini AA, et al. (2024) Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(23), 5333.

Ball?? JK, et al. (2024) PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study. *BMC cancer*, 24(1), 1127.

Ahn BC, et al. (2024) Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer. *Cancer research and treatment*, 56(1), 70.